Close Menu

Technology Review profiles next-gen sequencing company Pacific Biosciences, which has raised $178 million to develop its zero mode waveguide technology. According to the article, the company's got 12 prototype instruments churning out data. And with read lengths targeting thousands of bases, PacBio has its eye on the medical market, where "we'll be able to detect rare mutations with unprecedented accuracy," says CTO Steve Turner.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.